Daiichi Begins Phase 1/2 Trial Of MRNA Covid19 Vaccine, DS-5670 In Japan

Daiichi Sankyo Company announced it has started the first vaccinations in a phase 1/2 clinical trial in Japan of an mRNA vaccine (DS-5670) that is being developed by the company against the novel coronavirus infectious disease (Covid-19).DS-5670 is being developed by Daiichi Sankyo’s proprietary novel nucleic acid delivery technology. Daiichi Sankyo is leading the research and development, in collaboration with the University of Tokyo’s Institute of Medical Science, through “Development of vaccines for the novel coronavirus disease (Second Round),” (company-initiated), which is promoted by the Japan Agency for Medical Research and Development. Results from preclinical studies suggest that positive safety and efficacy of DS-5670 have been confirmed.The phase 1/2 trial is being conducted in Japan in a total of 152 healthy adults, including elderly individuals, to evaluate the safety and immunogenicity1 of the vaccine and thereby estimate the recommended dose of DS-5670. The endpoints for safety are adverse events and reactions, and those for immunogenicity are neutralizing antibody titer and IgG titer.As a Japanese pharmaceutical company with specialty in developing vaccines, Daiichi Sankyo is striving to help restore safety and security in society through the early eradication of Covid-19, which it hopes to achieve by pursuing the development of DS-5670, a Japan-made vaccine against Covid-19, as well as by generating adequate supplies of DS-5670 as soon as possible.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!